Sekar Seshagiri Ph.D

President, Science & Education

Somasekar (Sekar) Seshagiri leads SGRF’s scientific research activities and is the driving force behind the foundation’s educational outreach activities including conferences. He chairs SGRF’s Nextgen Genomics, Biology, Bioinformatics and Technologies (NGBT) international meeting

A resident of San Francisco Bay Area, Seshagiri is Co-founder and Chief Scientific Officer for ModMab Therapeutics. Before that he spent 21 years at Genentech, most recently as Associate Director and Staff Scientist. During his tenure he established a state-of-the-art genomic laboratory, conducted research in cancer and cell signaling areas and participated in drug development.

His research work has been at the forefront of understanding underlying genetic changes in cancer genomes through systematic identification of somatic mutations in large number of cancer types and subtypes using next generation sequencing and other novel techniques. Seshagiri and team have applied computational methods and functional assays to understand the role of cancer specific mutations in oncogenic signaling leading to new target discovery for therapeutic intervention.

He has authored and co-authored over eighty articles in peer-reviewed journals including Science and Nature. Seshagiri holds a Bachelor of Science in Agriculture and a Master of Science in Biotechnology from Tamil Nadu Agricultural University, Coimbatore, India. He is also a recipient of a Master of Science (Software Engineering) from Golden Gate University, San Francisco, US and a Ph.D. in Genetics from the University of Georgia, Athens, GA, US. He did his postdoctoral work in Oncology and Bioinformatics at Genentech.

  • Exome sequencing reveals a novel splice site variant in HUWE1 gene in patients with suspected Say-Meyer syndrome.

    Muthusamy B, Nguyen TT, Bandari AK, Basheer S, Selvan LDN, Chandel D, Manoj J, Gayen S, Seshagiri S, Chandra Girimaji S, Pandey A.
    Eur J Med Genet. 2019 Feb 21. pii: S1769-7212(18)30478-6. doi: 10.1016/j.ejmg.2019.02.007.
    PMID: 30797980

  • Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.

    Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S.
    Cancer Cell. 2018 Nov 12;34(5):792-806.e5. doi: 10.1016/j.ccell.2018.09.010. Epub 2018 Oct 25.
    PMID: 30449325

  • Next generation sequencing identifies novel disease-associated BEST1 mutations in Bestrophinopathy patients.

    Nguyen TT, Poornachandra B, Verma A, Mehta RA, Phalke S, Battu R, Ramprasad VL, Peterson AS, Ghosh A, Seshagiri S.
    Sci Rep. 2018 Jul 5;8(1):10176. doi: 10.1038/s41598-018-27951-8.
    PMID: 29976937

  • Comprehensive analysis of single molecule sequencing-derived complete genome and whole transcriptome of Hyposidra talaca nuclear polyhedrosis virus.

    Nguyen TT, Suryamohan K, Kuriakose B, Janakiraman V, Reichelt M, Chaudhuri S, Guillory J, Divakaran N, Rabins PE, Goel R, Deka B, Sarkar S, Ekka P, Tsai YC, Vargas D, Santhosh S, Mohan S, Chin CS, Korlach J, Thomas G, Babu A, Seshagiri S.
    Sci Rep. 2018 Jun 12;8(1):8924. doi: 10.1038/s41598-018-27084-y. Erratum in: Sci Rep. 2018 Aug 31;8(1):13274.
    PMID: 29895987